223 related articles for article (PubMed ID: 10551494)
1. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
2. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH; Hafley G; Harrington RA; Peterson ED; Ferguson TB; Lorenz TJ; Goyal A; Gibson M; Mack MJ; Gennevois D; Califf RM; Kouchoukos NT;
JAMA; 2005 Nov; 294(19):2446-54. PubMed ID: 16287955
[TBL] [Abstract][Full Text] [Related]
4. E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
Mann MJ
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):171-6. PubMed ID: 9593059
[No Abstract] [Full Text] [Related]
5. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
[TBL] [Abstract][Full Text] [Related]
6. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
Conte MS; Lorenz TJ; Bandyk DF; Clowes AW; Moneta GL; Seely BL
Vasc Endovascular Surg; 2005; 39(1):15-23. PubMed ID: 15696244
[TBL] [Abstract][Full Text] [Related]
7. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.
Ehsan A; Mann MJ; Dell'Acqua G; Tamura K; Braun-Dullaeus R; Dzau VJ
Circulation; 2002 Apr; 105(14):1686-92. PubMed ID: 11940548
[TBL] [Abstract][Full Text] [Related]
8. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
Morishita R; Gibbons GH; Horiuchi M; Ellison KE; Nakama M; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5855-9. PubMed ID: 7597041
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.
Tomita N; Kim JY; Gibbons GH; Zhang L; Kaneda Y; Stahl RA; Ogborn M; Venderville B; Morishita R; Baran D; Dzau VJ
Int J Mol Med; 2004 May; 13(5):629-36. PubMed ID: 15067361
[TBL] [Abstract][Full Text] [Related]
10. Early growth response gene-1 decoy oligonucleotides inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of autogenous vein graft in rabbits.
Wang X; Mei Y; Ji Q; Feng J; Cai J; Xie S
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):50-4. PubMed ID: 25820759
[TBL] [Abstract][Full Text] [Related]
11. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.
Maeshima Y; Kashihara N; Yasuda T; Sugiyama H; Sekikawa T; Okamoto K; Kanao K; Watanabe Y; Kanwar YS; Makino H
J Clin Invest; 1998 Jun; 101(11):2589-97. PubMed ID: 9616230
[TBL] [Abstract][Full Text] [Related]
13. E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
Cho WH; Lee SO; Kim HT; Ahn JD; Lee IK
Transplant Proc; 2005; 37(1):77-9. PubMed ID: 15808553
[TBL] [Abstract][Full Text] [Related]
14. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model.
Miyake T; Aoki M; Shiraya S; Tanemoto K; Ogihara T; Kaneda Y; Morishita R
J Mol Cell Cardiol; 2006 Sep; 41(3):431-40. PubMed ID: 16762361
[TBL] [Abstract][Full Text] [Related]
16. The role of ex-vivo gene therapy of vein grafts with Egr-1 decoy in the suppression of intimal hyperplasia.
Peroulis M; Kakisis J; Kapelouzou A; Giagini A; Giaglis S; Mantziaras G; Kostomitsopoulos N; Karayannacos P; Macheras A
Eur J Vasc Endovasc Surg; 2010 Aug; 40(2):216-23. PubMed ID: 20537569
[TBL] [Abstract][Full Text] [Related]
17. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
18. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T
Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor.
Akimoto M; Hangai M; Okazaki K; Kogishi J; Honda Y; Kaneda Y
Exp Eye Res; 1998 Oct; 67(4):395-401. PubMed ID: 9820786
[TBL] [Abstract][Full Text] [Related]
20. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
